Acquisition of new mutations or pre-existing genetic alterations is linked to disease progression in NSCLC patients with EGFR mutations (20–23), and the highly heterogeneous and complex genetic landscape of this type of cancer impacts clinical outcomes. Here, EGFR is linked to cancer.